Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout

This article was originally published in The Pink Sheet Daily

Executive Summary

Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.

You may also be interested in...



Credit Woes Hit Pharma

The biggest pharmaceutical companies are least affected by the current credit crisis due to their strong balance sheets and hefty piles of cash, yet even they are finding debt is more expensive and harder to obtain. Big biotechs also have billions of dollars in cash and marketable securities. Smaller, development stage companies, however, are more fragile because their existence depends on their ability to raise money to fund their R&D.Specialty pharma falls in between big pharma and biotech: the group is vulnerable, but not as much as biotech. The lack of access to capital makes doing deals tougher and more expensive.

AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study

Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.

AtheroGenics Completes Enrollment Of Phase III AGI-1067 Diabetes Study

Interim data from the randomized, double-blind, placebo-controlled trial are expected in the second quarter of 2008.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel